Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children
Completed · Phase 3
Conditions studied: HIV Infections
In brief
The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining virologic suppression in HIV-1 infected children.
Key facts
- Study ID
- NCT00528957
- Run by
- Gilead Sciences
- People needed
- 97
- Starts
- 2006-12-28
- Expected to finish
- 2017-08-16
- Last updated by the study team
- 2018-03-14
Who can join
Age: 2 and older, up to 15. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jeffrey Goodman Special Care Clinic — Los Angeles, California, United States
- University California Los Angeles, School of Medicine, Pediatric, Infectious Diseases — Los Angeles, California, United States
- Children's Diagnostic and Treatment Center, Inc — Fort Lauderdale, Florida, United States
- University of Florida, Jacksonville — Jacksonville, Florida, United States
- St. Christopher's Hospital for Children — Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States
- Hospital del Nino — Panama City, Panama
- Great Ormond Street Hospital — London, United Kingdom
- Imperial College London, Paediatrics Infectious Diseases — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.